Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Nov;86(11):1010-3.
doi: 10.1111/j.1349-7006.1995.tb03013.x.

Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma

K Shimizu  1 , Y Miyao, M Tamura, H Kishima, M Ohkawa, E Mabuchi, M Yamada, T Hayakawa, K Ikenaka
Affiliations

Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma

K Shimizu et al. Jpn J Cancer Res. 1995 Nov.

Abstract

Intravenous gene transfer using recombinant retroviruses tends to suffer from a low infectious viral titer when conducted in vivo. This is, in part, caused by complement-mediated proteolytic inactivation of the retrovirus in human serum. However, if the retroviruses were directly injected into the brain, they might not be inactivated. Supernatant from amphotropic retrovirus-producing cells harboring the BAG vectors was incubated with sera or cerebrospinal fluid (CSF) of patients with gliomas or unrelated disorders. The retroviruses were severely inactivated in sera. However, no such inactivation was noted in CSF or fluid from the tumor bed of glioma patients. These data suggest that gene transfer using recombinant retroviruses could be done into the cavity after removal of the tumor in glioma patients.

PubMed Disclaimer

References

    1. ) Cone , R. and Mulligan , R. C.High efficiency gene transfer into mammalian cells: generation of helper‐free recombinant retroviruses with broad mammalian host range . Proc. Natl. Acad. Sci. USA , 81 , 6349 – 6353 ( 1984. ). - PMC - PubMed
    1. ) Culver , K. W. , Osborne , W. R. A. , Miller , A. D. , Fleisher , T. A. , Berger , M. , Anderson , W. F. and Blaese , R. M.Correction of ADA deficiency in human T lymphocytes using retroviral‐mediated gene transfer . Transplant. Proc. , 23 , 170 – 171 ( 1991. ). - PubMed
    1. ) Blaese , R. M. , Culver , K. W. , Chang , L. , Anderson , W. F. , Mullen , C. , Nienhuis , A. , Carter , C. , Dunbar , C. and Leitman , S.Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with the human ADA gene . Hum. Gene Ther. , 4 , 521 – 527 ( 1993. ). - PubMed
    1. ) Culver , K. W. , Van Gilder , J. , Link , C. J. , Carlstrom , T. , Yuh , W. , Koch , K. , Doorabars , S. , Wetjen , B. and Blaese , R. M.Clinical protocol; gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system . Hum. Gene Ther. , 5 , 343 – 379 ( 1994. ). - PubMed
    1. ) Culver , K. W. , Ram , Z. , Wallbridge , S. , Ishii , H. , Oldfield , E. H. and Blaese , R. M.In vivo gene transfer with retroviral vector‐producer cells for treatment of experimental brain tumors . Science , 256 , 1550 – 1552 ( 1992. ). - PubMed

MeSH terms

Substances

LinkOut - more resources